1.Maskin, CS, Sinoway, L, Chadwick, B, Sonnenblick, EH, Le Jemtel, TH.Sustained hemodynamic and clinical effects of a new cardiotonic agent, WIN 47203, in patients with severe congestive heart failure. Circulation 1983; 67: 1065–1070.
2.Alousi, AA, Canter, JM, Montenaro, MJ, Fort, DJ, Ferrari, RA.Cardiotonic activity of milrinone, a new and potent cardiac bipyridine, on the normal and failing heart of experimental animals. J Cardiovasc Pharmacol 1983; 5: 792–803.
3.Silver, PJ, Harris, AL, Canniff, PC, et al.Phosphodiesterase isozyme inhibition, activation of the cAMP system, and positive inotropy mediated by milrinone in isolated guinea pig cardiac muscle. J Cardiovasc Pharmacol 1989; 13: 530–540.
4.LeJemtel, TH, Scortichini, D, Levitt, B, Sonnenblick, EH.Effects of phosphodiesterase inhibition on skeletal muscle vasculature. Am J Cardiol 1989; 63: 27a–30a.
5.Sinoway, LS, Maskin, CS, Chadwick, B, Forman, R, Sonnenblick, EH, Le Jemtel, TH.Long-term therapy with a new cardiotonic agent, WIN 47203: drug-dependent improvement in cardiac performance and progression of the underlying disease. J Am Coll Cardiol 1983; 2: 327–331.
6.Baim, DS, McDowell, AV, Cherniles, J, et al.Evaluation of a new bipyridine inotropic agent – milrinone – in patients with severe congestive heart failure. N Engl J Med 1983; 309: 748–756.
7.Hoffman, TM, Wernovsky, G, Atz, AM, et al.Prophylactic intravenous use of milrinone after cardiac operation in pediatrics (PRIMACORP) study. Prophylactic intravenous use of milrinone after cardiac operation in pediatrics. Am Heart J 2002; 143: 15–21.
8.Cavigelli-Brunner, A, Hug, MI, Dave, H, et al.Prevention of low cardiac output syndrome after pediatric cardiac surgery: a double-blind randomized clinical pilot study comparing dobutamine and milrinone. Pediatr Crit Care Med 2018; 19: 619–625.
9.Barnwal, NK, Umbarkar, SR, Sarkar, MS, Dias, RJ.Randomized comparative study of intravenous infusion of three different fixed doses of milrinone in pediatric patients with pulmonary hypertension undergoing open heart surgery. Ann Card Anaesth 2017; 20: 318–322.
10.Ushio, M, Egi, M, Wakabayashi, J, et al.Impact of milrinone administration in adult cardiac surgery patients: updated meta-analysis. J Cardiothorac Vasc Anesth 2016; 30: 1454–1460.
11.James, AT, Bee, C, Corcoran, JD, McNamara, PJ, Franklin, O, El-Khuffash, AF.Treatment of premature infants with pulmonary hypertension and right ventricular dysfunction with milrinone: a case series. J Perinatol 2015; 35: 268–273.
12.James, AT, Corcoran, JD, McNamara, PJ, Franklin, O, El-Khuffash, AF.The effect of milrinone on right and left ventricular function when used as a rescue therapy for term infants with pulmonary hypertension. Cardiol Young 2016; 26: 90–99.
13.McNamara, PJ, Shivananda, SP, Sahni, M, Freeman, D, Taddio, A.Pharmacology of milrinone in neonates with persistent pulmonary hypertension of the newborn and suboptimal response to inhaled nitric oxide. Pediatr Crit Care Med 2013; 14: 74–84.
14.Kumar, VHS, Dadiz, R, Koumoundouros, J, Guilford, S, Lakshminrusimha, S.Response to pulmonary vasodilators in infants with congenital diaphragmatic hernia. Pediatr Surg Int 2018; 34: 735–742.
15.Lee, J, Kim, GB, Kwon, HW, et al.Safety and efficacy of the off-label use of milrinone in pediatric patients with heart diseases. Korean Circ J 2014; 44: 320–327.
16.Bianchi, MO, Cheung, PY, Phillipos, E, Aranha-Netto, A, Joynt, C.The effect of milrinone on splanchnic and cerebral perfusion in infants with congenital heart disease prior to surgery: an observational study. Shock 2015; 44: 115–120.